Patents by Inventor Peter Ulvskov

Peter Ulvskov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230331961
    Abstract: Disclosed herein are composite materials comprising amylose, cellulose nanofibres or cellulose nanocrystals, and a plasticiser. The amylose is of high purity, specifically containing little or no amylopectin. The cellulose nanofibres or cellulose nanocrystals act to reinforce the disclosed composite materials. Also disclosed are methods of producing such composite materials, and their use.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 19, 2023
    Inventors: Bodil Jørgensen, Peter Ulvskov, Andreas Blennow, Marwa Faisal
  • Patent number: 10753041
    Abstract: Processes for producing cellulose microfibrils from herbaceous plant material using enzyme compositions, the cellulose microfibrils obtained from the processes and their uses, and compositions comprising the cellulose microfibrils are described.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 25, 2020
    Assignees: CELLUCOMP LTD., NOVOZYMES A/S, UNIVERSITY OF COPENHAGEN
    Inventors: David Hepworth, Eric Whale, Bjoern Lennart Pierre Alexander Cassland, Henrik Lund, Lisbeth Kalum, Peter Ulvskov, Bodil Jørgensen
  • Publication number: 20170167079
    Abstract: Processes for producing cellulose microfibrils from herbaceous plant material using enzyme compositions, the cellulose microfibrils obtained from the processes and their uses, and compositions comprising the cellulose microfibrils are described.
    Type: Application
    Filed: May 21, 2015
    Publication date: June 15, 2017
    Inventors: David HEPWORTH, Eric WHALE, Bjoern Lennart Pierre Alexander CASSLAND, Henrik LUND, Lisbeth KALUM, Peter ULVSKOV, Bodil JØRGENSEN
  • Patent number: 9024110
    Abstract: This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon ?2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: May 5, 2015
    Inventors: Zhang Yang, Damian Paul Drew, Emma Adhiambo Arigi, Peter Ulvskov, Steven B. Levery, Eric Bennett, Henrik Clausen, Brent Larsen Petersen
  • Publication number: 20120117686
    Abstract: The present invention provides compositions and methods for increasing the level of mannosylglycerate in plants. Plants with increased levels of mannosylglycerate exhibit enhanced tolerance to stress, e.g., drought.
    Type: Application
    Filed: May 4, 2010
    Publication date: May 10, 2012
    Applicants: THE REGENTSOF THE UNIVERSITY OF CALIFORNIA, AARHUS UNIVERSITY, UNIVERSITY OF COPENHAGEN
    Inventors: Henrik Vibe Scheller, Jesper Harholt, Peter Ulvskov
  • Publication number: 20110237782
    Abstract: This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon ?2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation.
    Type: Application
    Filed: March 23, 2011
    Publication date: September 29, 2011
    Inventors: Zhang Yang, Damian Paul Drew, Emma Adhiambo Arigi, Peter Ulvskov, Steven B. Levery, Eric Paul Bennett, Henrik Clausen, Brent Larsen Petersen
  • Patent number: 6797861
    Abstract: “The present invention relates to DNA sequences, comprising nucleic acid fragments encoding dehiscence zone-selective proteins, particularly cell wall hydrolases such as polygalacturonases, and their use for modifying dehiscence properties in plants, more particularly pod dehiscence properties in Brassica napus.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: September 28, 2004
    Assignee: Bayer BioScience NV
    Inventors: Peter Ulvskov, Robin Child, Henri Van Onckelen, Els Prinsen, Bernhard Borkhardt, Lilli Sander, Morten Petersen, Gert Bundgard Poulsen, Johan Botterman
  • Publication number: 20030159178
    Abstract: Methods for providing transgenic plants and parts hereof that, relative to the wild type state, is modified in a complex cell wall polysaccharide structure including pectins and hemicelluloses, the modification being in the overall glycosidic linkage pattern or the monosaccharide profile, comprising transforming a plant cell with a nucleotide sequence that causes an altered production of a complex cell wall polysaccharide-modifying enzyme such as endo-rhamnogalacturonan hydrolase, an endo-rhamnogalacturonan lyase, an endo-galactanase, an endo-arabinanase, an arabinofuranosidase, a galactosidase such as a beta-galactosidase, a xylosidase and an exo-galacturosidase. The modification can occur in vivo or post harvest, in which latter case the modifying enzyme is separated in the growing plant from its substrate, e.g. by targeting the enzyme to the Golgi, the endoplasmic reticulum or a vacuole, or is in a form that is inactive in the plant.
    Type: Application
    Filed: December 20, 2002
    Publication date: August 21, 2003
    Inventors: Peter Ulvskov, Henk Shols, Richard Visser, Bernhard Borkhardt, Susanne Sorensen, Ronald Oomen, Jean-Paul Vincken, Michael Skjot, Chantal Doeswijk Voragen, Gerrit Beldman
  • Publication number: 20020184660
    Abstract: A plant is provided which contains at least one dehiscence zone (DZ)-selective chimeric gene incorporated in the nuclear genome of its cells, wherein said DZ-selective chimeric gene comprises the following operably linked DNA fragments:
    Type: Application
    Filed: May 21, 2002
    Publication date: December 5, 2002
    Applicant: Plant Genetic Systems, N.V.
    Inventors: Peter Ulvskov, Robin Child, Henri Van Onckelen, Els Prinsen, Bernhard Borkhardt, Lilli Sander, Morten Petersen, Gert Bundgard Poulsen, Johan Botterman
  • Patent number: 6420628
    Abstract: A plant is provided which contains at least one dehiscence zone (DZ)-selective chimeric gene incorporated in the nuclear genome of its cells, wherein said DZ-selective chimeric gene comprises the following operably linked DNA fragments: a) a transcribed DNA region encoding: 1) a RNA which, when produced in cells of a particular DZ of the plant, prevents, inhibits or reduces the expression in DZ cells of an endogenous gene of the plant encoding a cell wall hydrolase, particularly an endopolygalacturonase, or, 2) a protein or polypeptide, which when produced in DZ cells, kills or disables them or interferes with their normal metabolism, physiology or development; b) a plant expressible promoter which directs expression of transcribed DNA region at least in DZ cells, provided that if transcribed DNA region encodes a protein or polypeptide, or encodes an antisense RNA or ribozyme directed to a sense RNA encoded by an endogenous gene that is expressed in plant in cells other than DZ cells, plant expressible promot
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: July 16, 2002
    Assignee: Plant Genetic Systems, N.V.
    Inventors: Peter Ulvskov, Robin Child, Henri Van Onckelen, Els Prinsen, Bernhard Borkhardt, Lilli Sander, Morten Petersen, Gert Bundgard Poulsen, Johan Botterman